Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 111

Results For "US"

7124 News Found

USFDA inspects Piramal Pharma Lexington facility
Drug Approval | January 12, 2023

USFDA inspects Piramal Pharma Lexington facility

The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.


Merck named one of America’s Most JUST Companies by JUST Capital and CNBC
News | January 11, 2023

Merck named one of America’s Most JUST Companies by JUST Capital and CNBC

The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.


Lupin and Exeltis announce reimbursement approval of NaMuscla in Spain
News | January 10, 2023

Lupin and Exeltis announce reimbursement approval of NaMuscla in Spain

NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)


Zydus receives final approval from the USFDA for Febuxostat Tablets
Drug Approval | January 10, 2023

Zydus receives final approval from the USFDA for Febuxostat Tablets

Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).


Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).


Zydus launches Topiramate Extended-Release Capsules
Drug Approval | January 07, 2023

Zydus launches Topiramate Extended-Release Capsules

Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.


Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022


PMBI launches Jan Aushadhi Chyawanprash Special
News | January 06, 2023

PMBI launches Jan Aushadhi Chyawanprash Special

Chyawanprash Special will be available at all Jan Aushadhi Kendras


Rupala to inaugurate 29 MVUs and centralised call center in Thiruvananthapuram
Healthcare | January 05, 2023

Rupala to inaugurate 29 MVUs and centralised call center in Thiruvananthapuram

MVUs will provide diagnosis treatment, vaccination, artificial insemination, minor surgical interventions, audio-visual aids and extension services to farmers/animal owners at their doorstep in far flung areas.